Company Filing History:
Years Active: 2025
Title: Yi Lun - Innovator in Recombinant Human Acid Alpha-Glucosidase
Introduction
Yi Lun is a notable inventor based in Plainsboro, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. His work focuses on addressing critical health issues through innovative solutions.
Latest Patents
Yi Lun holds a patent for a recombinant human acid alpha-glucosidase. This invention provides a recombinant acid α-glucosidase and a pharmaceutical composition that includes this enzyme. The recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and features an increased content of N-glycan units bearing one or two mannose-6-phosphate residues compared to the content found in alglucosidase alfa. The patent also outlines methods for producing, purifying, and formulating the recombinant acid α-glucosidase for administration to subjects. Furthermore, it describes methods for treating diseases or disorders such as Pompe disease using this innovative composition.
Career Highlights
Yi Lun is currently associated with Amicus Therapeutics, Inc., where he continues to advance his research and development efforts. His work has been instrumental in creating therapies that improve the quality of life for patients suffering from rare genetic disorders.
Collaborations
Some of his notable coworkers include Hung V Do and Russell Gotschall, who contribute to the collaborative environment that fosters innovation and progress in their projects.
Conclusion
Yi Lun's contributions to the field of biotechnology, particularly through his patent on recombinant human acid alpha-glucosidase, highlight his role as an innovator dedicated to improving healthcare solutions. His work exemplifies the impact of scientific research on treating complex diseases.